Pharmacological SREBP-1 inhibition sensitized BRAFV600E-mutant therapy-resistant melanoma to BRAFV600E inhibitors both in vitro and in a pre-clinical PDX model [28]. The gene discussed is SREBF1; the disease is melanoma.